Show simple item record

dc.contributor.authorVegas Suárez, Sergio
dc.contributor.authorPisanò, Clarissa Anna
dc.contributor.authorRequejo Rodríguez, Catalina
dc.contributor.authorBengoetxea Odriozola, Harkaitz
dc.contributor.authorLafuente Sánchez, José Vicente
dc.contributor.authorMorari, Michele
dc.contributor.authorMiguélez Palomo, Cristina
dc.contributor.authorUgedo Urruela, Luisa
dc.date.accessioned2020-10-16T12:39:00Z
dc.date.available2020-10-16T12:39:00Z
dc.date.issued2020-09
dc.identifier.citationBritish Journal of Pharmacology 177(17) : 3957-3974 (2020)es_ES
dc.identifier.issn0007-1188
dc.identifier.issn1476-5381
dc.identifier.urihttp://hdl.handle.net/10810/46952
dc.description.abstractBackground and Purpose l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT(1A)partial agonist) have shown promising results in the treatment of PD and LID, however no 5-HT-based treatment has been approved in PD. The present study was aimed to investigate how thesubstantia nigra pars reticulata(SNr) is affected by buspirone and whether it is a good target to study 5-HT antidyskinetic treatments. Experimental Approach Buspirone was studied usingin vivosingle-unit, electrocorticogram, local field potential recordings along with microdialysis and immunohistochemistry in naive/sham, 6-hydroxydopamine (6-OHDA)-lesioned or 6-OHDA-lesioned andl-DOPA-treated (6-OHDA/l-DOPA) rats. Key Results Local buspirone inhibited SNr neuron activity in all groups. However, systemic buspirone reduced burst activity in 6-OHDA-lesioned rats (with or withoutl-DOPA treatment), whereas 8-OH-DPAT, a full 5-HT(1A)agonist induced larger inhibitory effects in sham animals. Neither buspirone nor 8-OH-DPAT markedly modified the low-frequency oscillatory activity in the SNr or synchronization within the SNr with the cortex. In addition, local perfusion of buspirone increased GABA and glutamate release in the SNr of naive and 6-OHDA-lesioned rats but no effect in 6-OHDA/l-DOPA rats. In the 6-OHDA/l-DOPA group, increased 5-HT transporter and decreased 5-HT(1A)receptor expression was found. Conclusions and Implications The effects of buspirone in SNr are influenced by dopamine loss andl-DOPA treatment. The present results suggest that the regulation of burst activity of the SNr induced by DA loss may be a good target to test new drugs for the treatment of PD and LID.es_ES
dc.description.sponsorshipEusko Jaurlaritza, Grant/Award Numbers: IT747-13, T747-13; Ministerio de Economia y Competitividad, Grant/Award Number: SAF2016-77758-Res_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2016-77758-Res_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectDOPA-induced dyskinesiaes_ES
dc.subjectabnormal involuntary movementses_ES
dc.subjectparkinsons-diseasees_ES
dc.subjectdorsal raphees_ES
dc.subjectsubstantia-nigraes_ES
dc.subjectnigrostriatal pathwayes_ES
dc.subjectsubthalamic nucleuses_ES
dc.subjectrat modeles_ES
dc.subjectserotonergic dysfunctiones_ES
dc.subject5-ht1a receptor stimulationes_ES
dc.title6-Hydroxydopamine lesion and levodopa treatment modif y the effect of buspirone in the substantia nigra pars reticulataes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15145es_ES
dc.identifier.doi10.1111/bph.15145
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.